A total of ten studies reported PFS data of NSCLC individuals stratified by PD-L1 tumor proportion score, and were found to benefit from PD-1 inhibitors compared to non-PD-1 inhibitor therapy with PD-L1 TPS <1% (HR 0.74; 95% CI, 0.58–0.95; P = 0.02), TPS ≥1% (HR 0.60; 95% CI, 0.42–0.86; P = 0.005), and TPS ≥50% (HR 0.58; 95% CI, 0.43–0.79; P = 0.0006), respectively, while PFS benefit was not observed in individuals with TPS 1–49% (HR 0.68; 95% CI, 0.41–1.12; P = 0.13) (Figure S1I and Table S2). This evidence concerns the gene CD274 and non-small cell lung carcinoma.